Influenza A Infection Clinical Trial
Official title:
Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection
Neuraminidase inhibitors (NAI) are effective anti-influenza antiviral treatment. During
their use in experimentally infected patients, it has been shown that the viral load
detected in the nasal fluid is decreasing significantly faster than in non treated patients.
During clinical practice, the emergence of NAI-resistant strains has been observed. These
strains remain rare, but their emergence seemed to be related to the mis-use of the NAI
products (insufficient duration or dosage). This observation as well as the detection of
NAI-resistant viruses in the community raises concerns about putative emergence of resistant
clones in the specific context of a pandemic, when the use of NAI will be very large in the
aim of reducing transmission, and subsequently the impact of the emerging virus.
In this context, it is important to determine the putative interest of alternative
strategies.
Although zanamivir and oseltamivir are both issued from the same class , this combination
may lead to a more rapid viral clearance in the infected cases, and to a reduction in the
emergence of resistant sub-clones, and alternatively, might lead to a competitive
inhibition. The evaluation of these combinations needs to be conducted in vivo.
Among available anti influenza antivirals, M2 blockers have been previously used. Although
their efficacy against A H5N1 remains to be ascertained, their use in combination with NAI
should also be evaluated in the context of a preparation for a possible pandemic and
determination of the stockpile.
Therefore, the evaluation of combination therapies in the treatment of a virologically
suspected influenza will be investigated in primary care during the winter season 2008-2009.
Study Schedule:
- Patient's follow up: 7 days with 10 visits V1, V2, V3, V4, V5 every 12 hours V6, V7,
V8, V9, V10 every 24 hours
- V1: conducted by the GP rapid test diagnostic for influenza A, urine pregnancy test for
women, inclusion /randomisation, nasal sample, initiation of treatment.
- V2 to V9: conducted by a nurse at the patient's home; nasal sample, symptoms scoring,
safety assessment (side effects)
- V 10: conducted by GP; medical evaluation (follow up evaluation)
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06401720 -
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
|